Patents Assigned to University of Pittsburgh of the Commonwealth System of Higher Education
  • Publication number: 20200017409
    Abstract: An optical sensor device includes an optical waveguide portion having a core, the core having a first refractive index, and a functional material layer coupled to the optical fiber portion, the functional material layer being made of a metal oxide material, the functional material layer being structured to have a second refractive index, the second refractive index being less than the first refractive index. The functional material layer may be a nanostructure material comprising the metal oxide material with a plurality of holes or voids formed therein such that the functional material layer is caused to have the second refractive index.
    Type: Application
    Filed: September 23, 2019
    Publication date: January 16, 2020
    Applicants: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, U.S. DEPARTMENT OF ENERGY
    Inventors: PENG CHEN, JACOB LORENZI POOLE, PAUL R. OHODNICKI, MICHAEL PAUL BURIC
  • Publication number: 20200009187
    Abstract: Methods are disclosed for inhibiting esophageal inflammation in a subject, that include administering to the esophagus of the subject with esophageal inflammation a therapeutically effective amount of an extracellular matrix (ECM) hydrogel. Methods are also disclosed for reducing esophageal stricture. Compositions are disclosed that include an esophageal extracellular matrix (ECM) hydrogel.
    Type: Application
    Filed: March 2, 2018
    Publication date: January 9, 2020
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Stephen Francis Badylak, Juan Diego Naranjo Gutierrez, Lindsey Tamiko Saldin
  • Publication number: 20200000973
    Abstract: The invention relates to biodegradable iron alloy-containing compositions for use in preparing medical devices. In addition, biodegradable crystalline and amorphous compositions of the invention exhibit properties that make them suitable for use as medical devices for implantation into a body of a patient. The compositions include elemental iron and one or more elements selected from manganese, magnesium, zirconium, zinc and calcium. The compositions can be prepared using a high energy milling technique. The resulting compositions and the devices formed therefrom are useful in various surgical procedures, such as but not limited to orthopedic, craniofacial and cardiovascular.
    Type: Application
    Filed: September 4, 2019
    Publication date: January 2, 2020
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: PRASHANT N. KUMTA, SUNG JAE CHUNG, PARTHA SAHA, OLEG VELIKOKHATNYI, MONI KANCHAN DATTA, DAE HO HONG, DA-TREN CHOU
  • Publication number: 20200000793
    Abstract: A method for preventing or treating skin damage in a radiotherapy subject, comprising topically administering to the subject a composition that includes a therapeutically effective amount at least one targeted nitroxide agent and at least one additional ingredient.
    Type: Application
    Filed: June 20, 2019
    Publication date: January 2, 2020
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Louis D. Falo, Jr., Joel S. Greenberger, Peter Wipf
  • Publication number: 20190389937
    Abstract: Described herein is a new antidote for the rapid elimination of carbon monoxide from hemoglobin, including brain, heart, and red cell hemoglobin. The disclosed therapy involves the use of modified human globins, particularly neuroglobins modified at residue 64 and cytoglobins modified at residue 81, which bind carbon monoxide with extremely high affinity. The monomeric mutant globins are infused into blood, where they rapidly and irreversibly sequester carbon monoxide, and thus limit toxic effects of carbon monoxide on cellular respiration and oxygen transport and utilization.
    Type: Application
    Filed: August 30, 2019
    Publication date: December 26, 2019
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Mark Thomas Gladwin, Jesus Tejero Bravo
  • Publication number: 20190381130
    Abstract: It is an object of the present invention to provide methods and compositions for protection of subjects from acute kidney injury by treating the subject with compounds that modulate the cell cycle. Modulating the cell cycle can comprise inducing G0/G1 cell cycle arrest, and/or inducing cell cycle progression. As demonstrated below, even a single administration of a compound which induces G0/G1 cell cycle arrest can protect subjects from AKI, and may be used prophylactically in advance of, or as a treatment following, various treatments or conditions that are known to be injurious to the kidney, followed optionally by release of the arrest. Once AKI is established, cell cycle progression can be induced to increase replacement of lost and damaged cells.
    Type: Application
    Filed: May 24, 2019
    Publication date: December 19, 2019
    Applicants: ASTUTE MEDICAL, INC., THE UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: PAUL MCPHERSON, JOHN A. KELLUM
  • Publication number: 20190376029
    Abstract: Methods are disclosed herein for producing human hepatocytes from human induced pluripotent stem cells. Also provided are transgenic rats for the expansion of human hepatocytes, such as those produced using the methods disclosed herein.
    Type: Application
    Filed: February 13, 2018
    Publication date: December 12, 2019
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Alejandro Soto-Gutierrez, Tomoji Mashimo, Alexandra Sylvie Collin de l'Hortet, Eduardo Cervantes Alvarez, Jorge Guzman Lepe, Kan Handa, Kazuki Takeishi, Yang Wang, Branimir Popovic
  • Publication number: 20190375710
    Abstract: A compound, or a pharmaceutically acceptable salt or isomer thereof, of Formula I: wherein R is hydrogen, alkyl, substituted alkyl, alkenyl, or substituted alkenyl; R1 is hydrogen, alkoxy, or substituted alkoxy; R2 is hydrogen, alkyl, or substituted alkyl; and R3 is hydrogen, alkyl, or substituted alkyl.
    Type: Application
    Filed: February 19, 2018
    Publication date: December 12, 2019
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, Universite Le Havre Normandie
    Inventors: Abdelhadi Rebbaa, Sebastien Comesse, Adam Daich, Martin Lawson, Catalin Pintiala
  • Publication number: 20190374226
    Abstract: The present disclosure concerns embodiments of an implantable perfusion device that can be implanted in an injured blood vessel to control bleeding without occluding the vessel. In one specific implementation, the perfusion device can be implanted percutaneously into a patient's descending aorta to control bleeding at the site of a ruptured portion of the aorta (known as torso hemorrhage) while still allowing for the antegrade flow of blood from a location upstream of the ruptured portion of the aorta to a location downstream of the ruptured portion of the aorta. The perfusion device can be left inside the patient as the patient is transported to a medical facility where the injury can be repaired. Following repair of the vessel, the perfusion device can be withdrawn from the patient.
    Type: Application
    Filed: August 6, 2019
    Publication date: December 12, 2019
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Bryan W. Tillman, William W. Clark, Sung Kwon Cho, Youngjae Chun
  • Publication number: 20190374562
    Abstract: The present invention relates to methods of treating infectious, inflammatory and post-traumatic disorders by administering various compounds newly discovered to have TLR4 inhibitory activity. In addition to methods of treatment, the present invention further provides for pharmaceutical compositions comprising said compounds, together with a suitable pharmaceutical carrier. Because TLR4 is the most upstream receptor in the pro-inflammatory LPS signaling cascade, treatments of the invention, which inhibit or antagonize TLR4 action, may avoid the pitfalls associated with other cytokine inhibitors that act further down the pathway and accordingly play a less specific (and perhaps non-critical) role.
    Type: Application
    Filed: April 17, 2019
    Publication date: December 12, 2019
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Peter Wipf, Matthew D. Neal, Sodhi P. Chhinder, David J. Hackam
  • Publication number: 20190374583
    Abstract: The present disclosure relates to the engraftment and proliferation of cells in fat-associated lymphoid clusters (“FALCs” or “milky spots”), which may be used to generate functional ectopic tissue. The present disclosure further provides methods and compositions for grafting and proliferating cells, in FALCs by activating the lymphotoxin beta receptor (LT?R) and/or NF-?B-inducing kinase (NIK) signaling pathway. The present disclosure also provides for methods and compositions to establish ectopic liver tissue in FALCs (milky spots) and to use such ectopic liver tissue for therapeutic benefit, and provides methods and compositions to generate ectopic kidney tissue in FALCs, which can be used in a subject for therapeutic benefit.
    Type: Application
    Filed: August 16, 2019
    Publication date: December 12, 2019
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventor: Eric Lagasse
  • Publication number: 20190367923
    Abstract: Antisense oligonucleotides (ASOs) that disrupt RNA-RNA interactions of influenza virus genome segments that are required for virus packaging are described. The ASOs can be used to inhibit influenza A virus replication in vitro and in vivo. Use of the ASOs for the treatment of a subject with an influenza virus infection is also described.
    Type: Application
    Filed: January 22, 2018
    Publication date: December 5, 2019
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Seema S. Lakdawala, Nara Lee
  • Publication number: 20190367462
    Abstract: Novel compounds are disclosed along with methods of inhibiting the TGF? pathway and methods of treating Idiopathic Pulmonary Fibrosis (IPF) using such compounds.
    Type: Application
    Filed: June 7, 2019
    Publication date: December 5, 2019
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventor: Beibei CHEN
  • Publication number: 20190359667
    Abstract: Recombinant transforming growth factor (TGF)-? monomers modified to inhibit dimerization and block TGF-? signaling are described. The recombinant TGF-? monomers lack the ability to bind and recruit TGF-? type I receptor (T?R1), but retain the capacity to bind the high affinity TGF-? type II receptor (T?RII), and in some instances, include mutations that increase their affinity for T?RII. Nucleic acid molecules and vectors encoding the recombinant TGF-? monomers are also described. Isolated cells, such as T cells, can be re-programmed with a TGF-? monomer-encoding nucleic acid or vector to secrete the monomer. Use of the recombinant TGF-? monomers and/or cells producing the recombinant TGF-? monomers, to inhibit TGF-? signaling, such as to treat disorders associated with aberrant TGF-? signaling, are also described.
    Type: Application
    Filed: November 17, 2017
    Publication date: November 28, 2019
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, National Research Council of Canada
    Inventors: Andrew Peterson Hinck, Traian Sulea
  • Publication number: 20190358232
    Abstract: Compounds, pharmaceutical compositions, and methods for reversing fosfomycin resistance are disclosed. Embodiments of the disclosed compounds inhibit fosfomycin-inhibiting enzymes. Some embodiments of the compounds are FosA inhibitors. The disclosed pharmaceutical compositions include (i) fosfomycin or a pharmaceutically acceptable salt thereof and (ii) a compound, or a pharmaceutically acceptable salt thereof, which inhibits a fosfomycin-inhibiting enzyme. A method of inhibiting growth of a fosfomycin-resistant bacterium includes contacting the bacterium with (i) fosfomycin or a pharmaceutically acceptable salt thereof and (ii) an effective amount of a disclosed compound or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: January 11, 2018
    Publication date: November 28, 2019
    Applicants: University of Pittsburgh - Of the Commonwealth System of Higher Education, University of Maryland, Baltimore
    Inventors: Nicolas Paul Sluis-Cremer, Adam Daniel Tomich, Yohei Doi, Eric J. Sundberg, Erik H. Klontz, Steven Fletcher
  • Publication number: 20190358176
    Abstract: The presently disclosed subject matter is directed to dual specificity mitogen-activated protein kinase phosphatase (DUSP-MKP) inhibitors that sensitize cancer cells immune cell killing and methods of using the disclosed DUSP-MKP inhibitors for the treatment of cancer.
    Type: Application
    Filed: July 16, 2019
    Publication date: November 28, 2019
    Applicant: University of Pittsburgh - of the Commonwealth System of Higher Education
    Inventors: Andreas Vogt, Christof Tobias Kaltenmeier, Michael T. Lotze, Waikok Michael Tsang
  • Publication number: 20190360056
    Abstract: The present invention relates to methods and compositions for determining whether a subject having prostate cancer is at greater risk of developing progressive disease, and methods of treating the subjects. It is based, at least in part, on the discovery that approximately 90% of men carrying at least one of the following fusion genes: TRMT11-GRIK2, SLC45A2-AMACR, MTOR-TP53BP1, LRRC59-FLJ60017, TMEM135-CCDC67 and CCNH-C5orf30 experienced prostate cancer recurrence, metastases and/or prostate cancer-specific death after radical prostatectomy (each examples of “progressive prostate cancer”), while these outcomes occurred in only 36% of men not carrying any of these fusion genes. It is also based, at least in part, on the discovery that no patient studied survived five years without recurrence if their primary prostate cancer contained a TRMT11-GRIK2 or MTOR-TP53BP1 fusion gene. It is also based, at least in part, on the discovery that the protein encoded by the MAN2A1-FER fusion gene exhibits kinase activity.
    Type: Application
    Filed: May 29, 2019
    Publication date: November 28, 2019
    Applicant: UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Jianhua Luo, Yangping Yu, Joel B. Nelson, George Konstantine Michalopoulos, Chien-Cheng Tseng, Ying Ding
  • Publication number: 20190350973
    Abstract: The present disclosure provides recombinant T cells that include a vector encoding one or more of peroxisome proliferator-activated receptor (PPAR) gamma coactivator 1-alpha (PGC1?), mitochondrial transcription factor A (Tfam), GA binding protein transcription factor alpha subunit (GABPA), and estrogen-related receptor alpha (ERR? ). Such recombinant T cells can also include a chimeric antigen receptor (CAR) or a recombinant T cell receptor (TCR). Methods of using these recombinant T cells in cancer immunotherapy are provided. Also provided are kits and compositions that can be used with such methods.
    Type: Application
    Filed: June 26, 2017
    Publication date: November 21, 2019
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventor: Greg M. Delgoffe
  • Publication number: 20190336591
    Abstract: Methods are disclosed for inhibiting the development of a tumor in a subject. The methods include administering to a subject a therapeutically effective amount of a dominant negative tumor necrosis factor (DN-TNF)-? protein and/or a nucleic acid encoding the DN-TNF-? protein. The DN-TNF-? protein and/or a nucleic acid encoding the DN-TNF-? protein can be administered alone or in combination with other agents.
    Type: Application
    Filed: December 14, 2016
    Publication date: November 7, 2019
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Nikola L. Vujanovic, Lazar Vujanovic
  • Publication number: 20190336540
    Abstract: This application provides methods of treating Krabbe disease, for example in an infant. Such methods can include immunosuppressing the patient, for example by administration of a myeloablative regimen, administering an umbilical cord blood transplant (UCBT) (such as an allogenic UCBT), and increasing expression of galactocerebrosidase (GALC) in the patient (e.g., by using gene editing).
    Type: Application
    Filed: January 19, 2018
    Publication date: November 7, 2019
    Applicant: University of Pittsburgh - Of the Commonwealth System of Higher Education
    Inventors: Maria Luisa Escolar, Paul Szabolcs